TrumpRx launched; Novo Nordisk to offer discounted Ozempic and promote Wegovy oral

Washington launches consumer drug hub amid pricing push

Trump administration officials unveil TrumpRx, a government‑backed website that routes cash‑paying patients to drugmakers offering discounts, in a bid to lower U.S. prescription costs. The platform does not sell medicines directly but points consumers to manufacturer sites and telehealth providers, and the White House says it will extend lower prices negotiated under a “most‑favored‑nation” framework for Medicaid to cash buyers. Centers for Medicare & Medicaid Services Administrator Dr. Mehmet Oz and designer Joe Gebbia join the rollout, underscoring the administration’s emphasis on user experience and broad industry participation.

TrumpRx links Novo Nordisk to discounted Ozempic for cash buyers

The administration says Novo Nordisk, along with Eli Lilly and others, signs participation agreements that allow specific medicines to be sold at reduced prices to cash‑paying consumers through TrumpRx referrals. Novo Nordisk agrees to make Ozempic available on the hub at about $350 per month, roughly half its retail list price, as part of the initiative to align U.S. prices with the lowest international rates. The program is positioned to benefit people without insurance or with limited coverage who are willing to forgo insurer channels, while manufacturers receive concessions such as tariff exemptions in exchange for participation.

Industry and policy researchers caution the practical reach and savings of TrumpRx remain uncertain. Analysts note announced discounts are measured against retail list prices, whereas insurers and government programs often secure substantially lower net prices after rebates and concessions, blurring the actual consumer benefit for the insured. Drugmakers portray TrumpRx as an expansion of existing direct‑to‑consumer discounting; Eli Lilly’s chief executive calls the approach an industry‑wide evolution, even as observers flag questions about continuity of care, eligibility, and whether the hub will materially shift market dynamics in the competitive GLP‑1 obesity space.

Novo Nordisk rolls out Wegovy oral consumer push

Separately, Novo Nordisk is launching its first big‑game commercial for the Wegovy oral semaglutide pill, promoting the FDA‑approved daily treatment as an option alongside diet and exercise. The company says the pill is broadly available through major pharmacies and select telehealth providers with a starting prescribed dose price of $149, part of a broader effort to spur consumer conversations about weight management.

Regulatory and competitive flare‑ups intensify

The market sees sharper competition as telehealth firm Hims & Hers announces a low‑priced semaglutide pill, prompting Novo Nordisk to threaten legal action and the FDA to warn it will act against unapproved copycat drugs. The episode heightens regulatory scrutiny and underscores persistent tensions over access, pricing and patient safety in the fast‑evolving GLP‑1 market.